Antibiotic Use in Facial Fracture Post Injury
Launched by METHODIST HEALTH SYSTEM · Jun 7, 2021
Trial Information
Current as of September 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of antibiotics after surgery for facial fractures, which are injuries that can occur due to accidents or trauma. The researchers want to find out if giving antibiotics for 3 days or 5 days after surgery can help prevent infections better than other treatment methods. Infections can be a common problem after surgery, and while short-term antibiotic use may not be enough, longer use can lead to other issues, such as allergic reactions or drug resistance.
To participate in this trial, you must be at least 18 years old and have suffered a blunt or penetrating injury that resulted in a facial fracture. Unfortunately, pregnant or breastfeeding women are not eligible to join. If you decide to participate, you will receive either a 3-day or 5-day course of antibiotics after your surgery, and researchers will monitor your recovery to see how well this treatment works in preventing infections. This trial is currently recruiting participants and aims to improve care for patients with facial injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female patient's ≥ 18 years of age.
- • Blunt and penetration injury.
- Exclusion Criteria:
- • Pregnant and breast feeding women.
About Methodist Health System
Methodist Health System is a leading healthcare provider dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and scientific inquiry, the organization leverages its state-of-the-art facilities and multidisciplinary expertise to conduct rigorous studies across various therapeutic areas. Methodist Health System collaborates with healthcare professionals, researchers, and industry partners to enhance the understanding of diseases and develop new treatment modalities, ensuring that cutting-edge therapies are accessible to the communities it serves. Through its clinical trial initiatives, Methodist Health System aims to contribute to the evolving landscape of medicine while prioritizing patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Patients applied
Trial Officials
Michael Truitt, M.D.
Principal Investigator
The Methodist Hospital Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials